0
0
Read Time:12 Second
NEW DELHI: The Indian Patent Office’s rejection of Johnson & Johnson’s (J&J) application for the paediatric version of its antituberculosis (TB) drug, bedaquiline, is likely to have broader implications for access to cost-effective TB treatment,…
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %